If you want to understand Lilly today, read its incretin patents as a single estate, not a pile of separate inventions. The 2025 grants, read in order, lay out a deliberate structure.

The foundation is the molecule. Incretins are the gut hormones — GIP and GLP-1 — that govern blood sugar and appetite, and Lilly's lead drug hits both. Grant US12252524B2 covers GIP/GLP1 co-agonist compounds, including formulation and dosing detail. That's the core deed.

“The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors.”— U.S. Patent No. 12,252,524 source

The next layer is method of use. US12295987B2 covers a method of using a GIP/GLP1 co-agonist for diabetes. A method patent protects the act of treating a condition with the drug — a separate claim from the molecule itself, with its own life.

The third layer is breadth across analogs. US12365716B2 covers incretin analogs and their uses — extending protection beyond the exact lead molecule to a family of related ones. That's how you stop a competitor from sidestepping with a near-copy.

Why does the layering matter to a reader sizing up the franchise? Because exclusivity isn't a single date. The compound, the method, and the analogs can expire at different times, and a challenger has to clear every live claim. Stagger them and the protected core keeps moving forward.

The short version: Lilly's incretin estate is a building, not a brick — compound on the ground floor, method above it, analogs filling out the structure. The 2025 grants are the company adding floors. Understanding that is the difference between seeing a looming cliff and seeing an actively defended franchise.